Cartesian Therapeutics (RNAC) has issued an update.
Cartesian Therapeutics, Inc. has successfully navigated significant corporate actions, gaining stockholder approval for pivotal proposals, including the issuance of common stock upon conversion of preferred stock and the implementation of a reverse stock split. Shareholders decisively voted in favor of the conversion, allowing the company to amend its designation for an automatic conversion post-merger. Additionally, the stockholders supported a reverse stock split at a 1-for-30 ratio, aimed at optimizing the company’s stock structure. This move is set to reduce the total outstanding shares and is expected to take effect on the Nasdaq under a new ticker symbol.
Find detailed analytics on RNAC stock on TipRanks’ Stock Analysis page.
